Enabling reliable development and manufacturing of advanced therapies and complex biologics through a next-generation CRDMO platform. Taiwan Bio-Manufacturing Corporation (TBMC) is a Taiwan-based pure-play CRDMO focused on supporting global pharmaceutical and biotechnology partners in advancing next-generation therapeutics. Built upon Taiwan’s strong biotechnology research foundation and world-class manufacturing ecosystem, TBMC integrates experienced GMP expertise with advanced production technologies. TBMC provides end-to-end CRDMO solutions across cell therapy, mRNA therapeutics, viral vectors, plasmid DNA, and complex biologics including ADCs and bispecific antibodies. With modular, flexible, and digital GMP facilities, strong IP protection, and an Asia-based manufacturing presence, TBMC enables global partners to accelerate development timelines, scale manufacturing capacity, and support regulatory compliance across international markets. Partner with TBMC to strengthen your global manufacturing strategy for next-generation therapies.
Taiwan Cell Manufacturing Co. Ltd
At Taiwan Cell Manufacturing Co. (tcmc), we specialize in delivering premium-quality lentiviral vectors (LVVs) and cell therapy products tailored to meet your needs. LVVs play an important role in genetic engineering of T cells, and we offer advanced solutions for LVV manufacturing to support gene-editing T cells, from R&D to full-scale commercialization. Our expertise also extends to the manufacturing of non-genetically modified cells as well, including DC, NK and stem cells. We understand the complex world of compliance, so every CDMO service we provide is accompanied by robust regulatory support for your CMC package. From groundbreaking research to life-changing therapies, tcmc is your trusted partner in developing next generation therapies.
SyVento BioTech
SyVento BioTech is an innovative biotech partner offering end-to-end capabilities to develop, formulate and manufacture next-generation mRNA-based products and innovative medicines. Leveraging unique know-how and customer-centric flexibility, the company delivers comprehensive services, including preclinical/clinical drug development, RUO/GMP-grade mRNA synthesis, manufacturing of GMP commercial/clinical batches, and aseptic fill & finish—all under one roof. With a state-of-the-art facility located in the EU (Poland), SyVento BioTech specializes in liposomal and LNP technology, providing tailored solutions for the encapsulation and delivery of therapeutic molecules, such as: RNA, DNA, CRISPR, small molecules, proteins and peptides. The company supports customers on each step of the project, including quality control, analytics, bioassay, regulatory support, warehousing and project management. | SyVento BioTech is an innovative biotech partner offering end-to-end capabilities to develop, formulate and manufacture next-generation mRNA-based products and innovative medicines. Leveraging unique know-how and customer-centric flexibility, the company delivers comprehensive services, including preclinical/clinical drug development, RUO/GMP-grade mRNA synthesis, manufacturing of GMP commercial/clinical batches, and aseptic fill & finish – all under one roof. With a state-of-the-art facility located in the EU (Poland), SyVento BioTech specializes in liposomal and LNP technology, providing tailored solutions for the encapsulation and delivery of therapeutic molecules, such as: RNA, DNA, CRISPR-Cas9, small molecules, proteins and peptides. The company supports customers on each step of the project, including quality control, analytics, bioassay, regulatory support, warehousing and project management.
Symbiosis
Symbiosis Pharmaceutical Services is a contract manufacturing organisation (CMO) specialising in the GMP manufacture and sterile fill/finish of vials for clinical trials and commercial supply. Regulatory compliance, technical capability and operational flexibility are at its core. Manufacturing from a purpose-built FDA inspected and MHRA-licensed facility, the CMO can handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs. Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product sterile manufacturing. | Symbiosis is a global, client-focused, contract manufacturing organisation (CMO) offering GMP aseptic manufacture for clinical trials through to commercial supply. Utilising batch strategies closely aligned with the latest regulatory framework, Symbiosis empowers drug developers to meet their project milestones through rapid access to fill-finish slots. Our purpose-built, FDA-inspected and MHRA-licensed manufacturing suites are designed with cytotoxic APIs in mind. Working with liquid and lyophilised formulations, our expert in-house team has over ten years of experience in taking a wide range of from drug substances to QP release e.g. mAbs, vaccines, small molecules, ADCs, ATMPs, etc. As trusted partners, Symbiosis are dedicated to supporting our clients facilitate safe, life-saving injectable drug therapies, without delay. Get in touch to begin your fill-finish program. | Symbiosis is a global contract manufacturing organisation (CMO) offering drug product GMP aseptic manufacture for clinical trials through to commercial supply. Closely aligned with the latest regulatory framework including Annex 1 and BSL-2, Symbiosis empowers drug developers to meet their project milestones through rapid access to fill-finish slots. Our purpose-built, FDA-inspected and MHRA-licensed manufacturing suites are designed to accommodate cytotoxic APIs. Working with liquid and lyophilised formulations, our expert in-house team handle a range of modalities from drug substance to QP release e.g. mAbs, vaccines, small molecules, ADCs, ATMPs, etc. As trusted partners, Symbiosis are dedicated to supporting our clients facilitate safe, life-saving injectable drug therapies, without delay.
Space Peptides
Headquartered in Switzerland with global operations, Space Peptides provides End-to-End pharmaceutical Peptide CRDMO services at Premium Speed & Quality – covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.
Simpson Biotech Co., Ltd.
Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag. New product launched in 2023: 1. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation, 2. Potent anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; 2. World’s first high purity (chitobiose+chitotriose > 90%) oligo chitosan for weight, diabetes and triglyceride control; 3. Hydrolyzed Fucoidan for immune & glucose control. SBC has won numerous awards with 54 patents issued. —–>—– 【Natural Compound as Oral Drug development for NAFLD/NASH】 Reduce liver triglyceride and cholesterol in NAFLD Reduce serum triglyceride and cholesterol in NAFLD Reduce liver fat deposition in NAFLD Reduce ALT and AST in NAFLD Anti-inflammation and oxidative stress Anti-fibrosis US, CN, TW patents granted 【Recombinant Protein Expression/Purification Platform (HERPEPSTM) and Products】 Patent Recombinant Protein Platform & CDMO Service – Cost-effective recombinant protein expression & purification system; From gene to protein Starch Binding Protein (SBP) as an affinity tag One-step purification of recombinant protein by starch Protein immobilization on starch enhanced the thermostability & shelf life Easy to scale up: From 100L lab-scale concept proof to 8000L mass production Ideal for industrial, food, feed enzymes Self-owned Tool Box for Protein Expression in Pichia pastoris Methanol-induced or Methanol-free expression Antibiotics-free expression host Genetic manipulation of expression strain with high yield Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical studies. One clinical study for Rheumatoid Arthritis (RA) has been completed. Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 Alcoholic Hangover Release : Antrodia cinnamomea mycelia Neuroprotective & Memory Enhancement : Ginsenoside compound K Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia Heart Protection : Agaricus blazei murill Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts Fermented Vegetables & Grains Concentrate as prebiotics Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. IFN-γ Stimulant Anti-viral Antibiotic alternative Anti-coccidia Increase feed efficiency US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag and in-house non-methanol, antibiotics-free expression strain. Highlight in 2024: 1. Recombinant protein OEM/ODM with proprietary yeast platform, 2. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation. 3. Antrodin as potent oral drug for NAFLD/NASH; 4. Natural anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; SBC has won numerous awards with 54 patents issued. —–>—– 【Recombinant Protein OEM/ODM with Proprietary Yeast Platform】 – One-step purification of recombinant protein by starch – Protein immobilization on starch enhanced the thermostability & shelf life – Easy to scale up: From 100L lab-scale concept proof to 8000L mass production – Ideal for industrial, food, feed enzymes – Turn-key licensed(non-exclusive) to global feed company already > – In-house Non-Methanol promoter compared to AOX1 – Antibiotics-free expression strain: Eco-friendly – Genetic manipulation of expression strain with high yield – Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical study for Rheumatoid Arthritis (RA). – Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 – Alcoholic Hangover Release : Antrodia cinnamomea mycelia – Neuroprotective & Memory Enhancement : Ginsenoside compound K – Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan – Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia – Heart Protection : Agaricus blazei murill – Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk – OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts – Fermented Vegetables & Grains Concentrate as prebiotics – Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. – IFN-γ Stimulant – Anti-viral – Antibiotic alternative – Anti-coccidia – Increase feed efficiency – US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. specializes in bio-fermentation development and commercialization: 1. Medicinal fungi for dietary supplements and early-stage drug discovery, specifically Hepasim®. 2. SimpsonPure health supplements portfolios. 3. Patented platform developing for recombinant protein expression and purification. We are seeking partnerships for the development of new recombinant proteins.
Sikich
Sikich LLP is a business and technology consultancy who’s close to 1,500 team members provide advisory, consulting, and technology services to clients in life sciences, manufacturing, professional services, and other industries. The company’s life sciences practice spans the industry and supports more than 200 life sciences clients, including biotechnology and biopharmaceutical companies, CROs, and lab diagnostic companies. As a leading life science technology consultant, we can help you streamline operations and ensure compliance, allowing stakeholders to do what they do best: develop new medicines for patients who need them. | At Sikich, we empower life sciences organizations through strategic planning, regulatory expertise, and digital modernization. From inception to commercialization, we specialize in planning, regulatory, quality, and compliance, leveraging cutting-edge technologies like Oracle NetSuite, Honeywell’s TrackWise Digital, and Kneat’s solutions to streamline operations and accelerate innovation. Our tailored approach combines deep industry knowledge with advanced digital tools, ensuring compliance, enhancing efficiency, and reducing time-to-market for life-changing therapies. A focus on built in audit trails, roles-based control and automated reporting ensure compliance with FDA 21 CFR Part 11, SOX and EU Annex 11. With a commitment to precision, integrity, and transformation, we help companies navigate complex regulatory landscapes and embrace the future of life sciences with confidence. Plan smarter. Modernize faster. Innovate with impact.
Shanghai Taichu Biotechnology Co., Ltd.
Taichu group was founded in 2020, providing contract research, development and manufacturing services to pharmaceutical and biotech companies. Our service platforms include early discovery and design of complex antibodies such as multispecific antibodies, nanobodies, fusion proteins etc. Our GLP- and AAALAC- certified animal facility provides preclinical studies (PK/PD), safety evaluation (Toxicology) for a various modality of drug candidates, such as small molecules, biologics, ADC, CGT products, and RNAi, ASO, mRNA molecules. For development and manufacturing of complex antibodies, our CDMO (Tarlead) has experienced teams, well-established laboratories and facility for process development, drug substance production and drug product manufacturing, ready to meet your needs and timelines. | Taichu Group is a biotechology enterprise with a core advantage in “CRO+CDMO integrated services”, providing end-to-end solutions for global innovative drug development from early discovery through preclinical research. Headquartered in Shanghai’s Lingang Special Area, the Group operates through its subsidiaries: Taichu Bio (Pre-Clinical Research), AceMab Ltd (Antibody Discovery & Design), Tarlead Biologics (Biologics Development & Manufacturing), TJR Bio (Nucleic Acid Drug Process & Manufacturing), and Taichu (Shenzhen) (Innovative Therapeutic Development Advisory). Guided by the philosophy “Advocate of Ethics and Integrity, Quest for Verity”, we streamline R&D workflows and accelerate therapeutic advancement for global partners. Our synergistic service model bridges key gaps between discovery and commercialization, reinforcing our role as a strategic enabler in the biopharmaceutical innovation value chain.